839 participants
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-20
- Start Date:
- 2019-08-05
- Completion:
- 2024-08-28
Conditions
- Metastatic Colorectal Cancer
Interventions
- BIOLOGICAL
- DRUG